Walgreens Boots Alliance (NASDAQ:WBA) Releases FY25 Earnings Guidance

Walgreens Boots Alliance (NASDAQ:WBA) updated its FY25 earnings guidance on Tuesday. The company provided earnings per share guidance of $1.40-$1.80 for the period, compared to the consensus earnings per share estimate of $1.70. The company issued revenue guidance of $147.0-$151.0 billion, compared to the consensus revenue estimate of $147.74 billion. Walgreens Boots Alliance also updated its FY 2025 guidance to 1.400-1.800 EPS.

Walgreens Boots Alliance Price Performance

Shares of WBA opened at $10.42 on Wednesday. The stock has a 50-day moving average of $9.40 and a 200-day moving average of $13.23. Walgreens Boots Alliance has a one year low of $8.22 and a one year high of $27.05. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.31 and a current ratio of 0.65.

Walgreens Boots Alliance (NASDAQ:WBA) last announced its quarterly earnings data on Tuesday, October 15th. The pharmacy operator reported $0.39 EPS for the quarter, beating analysts’ consensus estimates of $0.36 by $0.03. Walgreens Boots Alliance had a positive return on equity of 12.63% and a negative net margin of 3.99%. The firm had revenue of $37.50 billion during the quarter, compared to analysts’ expectations of $35.75 billion. During the same quarter last year, the firm posted $0.67 earnings per share. The company’s revenue for the quarter was up 5.9% compared to the same quarter last year. On average, sell-side analysts anticipate that Walgreens Boots Alliance will post 2.85 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the stock. UBS Group decreased their target price on shares of Walgreens Boots Alliance from $17.00 to $12.00 and set a neutral rating for the company in a research report on Wednesday, July 3rd. Barclays lowered their price target on Walgreens Boots Alliance from $11.00 to $7.00 and set an underweight rating for the company in a research report on Tuesday, July 23rd. Evercore ISI decreased their price objective on shares of Walgreens Boots Alliance from $17.00 to $10.00 and set an in-line rating for the company in a research note on Friday, June 28th. JPMorgan Chase & Co. reduced their target price on Walgreens Boots Alliance from $20.00 to $15.00 and set an overweight rating for the company in a report on Friday, August 30th. Finally, Morgan Stanley dropped their price target on Walgreens Boots Alliance from $9.00 to $7.00 and set an underweight rating on the stock in a report on Friday, October 11th. Four investment analysts have rated the stock with a sell rating, eight have issued a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat, the company has an average rating of Hold and an average price target of $13.46.

About Walgreens Boots Alliance

Walgreens Boots Alliance, Inc operates as a healthcare, pharmacy, and retail company in the United States, the United Kingdom, Germany, and internationally. It operates through three segments: U.S. Retail Pharmacy, International, and U.S. Healthcare. The U.S. Retail Pharmacy segment engages in operation of the retail drugstores, health and wellness services, specialty, and home delivery pharmacy services, which offers health and wellness, beauty, personal care and consumables, and general merchandise.